SCHEMBL2004780

SCHEMBL2004780

N#CCc1c[nH]c2ccc(O)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 3/20 0.67
HTR2C P28335 7/20 0.61
HTR1A P08908 5/20 0.59
HTR2A P28223 5/20 0.59
HTR2B P41595 4/20 0.59
HTR1D P28221 4/20 0.59
CYP2D6 P10635 4/20 0.59
CYP2C9 P11712 3/20 0.59
TSHR P16473 3/20 0.59
CYP1A2 P05177 3/20 0.59
CYP3A4 P08684 3/20 0.59
HTR1B P28222 2/20 0.59
HTR7 P34969 2/20 0.59
HTR3E A5X5Y0 1/20 0.59
HTR3B O95264 1/20 0.59
DRD1 P21728 1/20 0.59
HTR1E P28566 1/20 0.59
HTR1F P30939 1/20 0.59
DRD3 P35462 1/20 0.59
RECQL P46063 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14964100 0.81 CSNK2A1 (0.63) CSNK2A1HTR2CHTR1AHTR2AHTR2B
SCHEMBL5424801 0.80 HTR2C (0.71) HTR2CHTR1AHTR2AHTR2BHTR1D
SCHEMBL14970013 0.80 CSNK2A1 (0.67) CSNK2A1HTR2CHTR1AHTR2AHTR2B
SCHEMBL446591 0.80 CSNK2A1 (0.67) CSNK2A1HTR2CHTR1AHTR2AHTR2B
SCHEMBL2005588 0.80 CSNK2A1 (1.00) CSNK2A1HTR2CHTR1AHTR2AHTR2B
SCHEMBL274224 0.80 CSNK2A1 (0.67) CSNK2A1HTR2CHTR1AHTR2AHTR2B
SCHEMBL2724522 0.80 MPO (0.68) CSNK2A1HTR2CHTR1AHTR2ATSHR
SCHEMBL28534064 0.79 HTR2C (0.74) HTR2CHTR1AHTR2AHTR2BHTR1D
SCHEMBL10566282 0.78 HTR7 (0.63) CSNK2A1HTR2CHTR1AHTR1DCYP2D6
SCHEMBL266613 0.77 NPSR1 (0.68) HTR2CHTR1AHTR2AHTR2BHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3307724-B1 (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES NAT UNIV SINGAPORE (SG) 2020-06-10 EP disclosed
EP-3307724-B1 (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES NAT UNIV SINGAPORE (SG) 2020-06-10 EP disclosed
US-10308631-B2 Selective anti-cancer compounds NATIONAL UNIVERSITY OF SINGAPORE (SG) 2019-06-04 US disclosed
US-10308631-B2 Selective anti-cancer compounds NATIONAL UNIVERSITY OF SINGAPORE (SG) 2019-06-04 US disclosed
US-20180179178-A1 SELECTIVE ANTI-CANCER COMPOUNDS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2018-06-28 US disclosed
US-20180179178-A1 SELECTIVE ANTI-CANCER COMPOUNDS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2018-06-28 US disclosed
US-20180179178-A1 SELECTIVE ANTI-CANCER COMPOUNDS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2018-06-28 US disclosed
WO-2016200339-A1 SELECTIVE ANTI-CANCER COMPOUNDS NATIONAL UNIVERSITY OF SINGAPORE (SG) 2016-12-15 WO disclosed
CN-105866303-A Detecting method for determining various neurotransmitters on the basis of in situ derivation 曲阜师范大学 2016-08-17 CN disclosed
US-8884020-B2 Indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2014-11-11 US disclosed
CN-102850324-A Indole compounds MICROBIA INC 2013-01-02 CN disclosed
US-7960544-B2 Useful indole compounds IRONWOOD PHARMACEUTICALS, INC. (US) 2011-06-14 US disclosed
US-20100197708-A1 INDOLE COMPOUNDS WELLS FARGO BANK, NATIONAL ASSOCIATION 2010-08-05 US disclosed
US-20090264653-A1 USEFUL INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. 2009-10-22 US disclosed
CN-101563337-A Indole compounds MICROBIA INC (US) 2009-10-21 CN disclosed
EP-2049520-A2 INDOLE COMPOUNDS Ironwood Pharmaceuticals, Inc. (US) 2009-04-22 EP disclosed
WO-2008019357-A2 INDOLE COMPOUNDS IRONWOOD PHARMACEUTICALS, INC. (US) 2008-02-14 WO disclosed
US-6750242-B1 Positive modulators of nicotinic receptor agonists ASTRAZENECA AB (SE) 2004-06-15 US disclosed
EP-1230216-A1 POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS AstraZeneca AB (SE) 2002-08-14 EP disclosed
WO-2001032619-A1 POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS ASTRAZENECA AB (SE) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308631-B2 Selective anti-cancer compounds CCNA1, CCNY, CCNT1 CSNK2A1 1142/4885HTR2C 4606/4885HTR1A 3722/4885
US-20180179178-A1 SELECTIVE ANTI-CANCER COMPOUNDS CCNA1, CCNY, CCNT1 CSNK2A1 1142/4885HTR2C 4606/4885HTR1A 3722/4885
US-20100197708-A1 INDOLE COMPOUNDS IDO1, IDO2, TPH2 CSNK2A1 1834/4885HTR2C 13/4885HTR1A 22/4885
US-20090264653-A1 USEFUL INDOLE COMPOUNDS FAAH, FAAH2, AANAT CSNK2A1 3901/4885HTR2C 46/4885HTR1A 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.